Biohaven
Biohaven Ltd is a commercial-stage biopharmaceutical enterprise headquartered in New Haven, Connecticut. The company specializes in the discovery, development, and commercialization of innovative therapeutics targeting neurological, psychiatric, and rare diseases, utilizing proprietary drug discovery platforms including glutamate modulation and myostatin inhibition. Principal revenue is derived through commercial pharmaceutical product sales of approved specialty medications and strategic pharmaceutical research licensing agreements. Biohaven Ltd is publicly listed on the New York Stock Exchange.
2 of the funds FundTelligence covers report a position in Biohaven.
- Legal name
- Biohaven Ltd
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Biohaven
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)